NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

The top 100 patients have a mOS from surgery of 58.4 months. That means that 50 patients will have reached about 5 years, or 15%. But if those 50 patients are all treatment, yes that represents 21.5% of early treatment patients living to 5 years, versus 15% living to 5 years with Optune (which is based on about 2 patients!), and historical data indicating just 5% live that long.